- Valeant (VRX) intends to its improve its $45.7B offer for Allergan (AGN) based of feedback that the Canadian company hopes to receive from Allergan shareholders during a Webcast about the deal on May 28.
- "We are prepared to pay a full and fair price, but, consistent with our track record, we will remain financially disciplined," Valeant said.
- The firm's comments come after Allergan formally rejected Valeant's proposal yesterday.
- Allergan's shares are +1.9% premarket. (PR)
at Zacks.com (Nov 18, 2014)